
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is well-positioned in the pharmaceutical market, with a diverse portfolio of products in immunology, oncology, and aesthetics, and a strong pipeline supported by recent acquisitions. The company shows promising growth potential, with strong TRx script growth in several key products and minimal impact from competitors in the near term. The company also demonstrates a commitment to sustainability and diversity, with formal governance structures in place to ensure responsible pricing decisions and promote diversity in leadership positions.
Bears say
AbbVie is facing multiple challenges as its core products, Humira, Skyrizi, and Rinvoq, experience pricing pressures and increased competition in the immunology segment. The recent IPR&D charge and acquisition of Allergan have also negatively impacted earnings and may not fully offset revenue decline from Humira's patent expiry. Upcoming catalysts, including clinical trial data and the planned Apogee acquisition, pose significant risks to the company's future performance, and the outlook remains uncertain.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares